Cargando…

Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period

BACKGROUND: Altered glutamatergic neurotransmission and neuropeptide levels play a central role in migraine pathomechanism. Previously, we confirmed that kynurenic acid, an endogenous glutamatergic antagonist, was able to decrease the expression of pituitary adenylate cyclase-activating polypeptide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tuka, Bernadett, Nyári, Aliz, Cseh, Edina Katalin, Körtési, Tamás, Veréb, Dániel, Tömösi, Ferenc, Kecskeméti, Gábor, Janáky, Tamás, Tajti, János, Vécsei, László
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229298/ https://www.ncbi.nlm.nih.gov/pubmed/34171996 http://dx.doi.org/10.1186/s10194-021-01239-1

Ejemplares similares

Cluster headache and kynurenines
por: Tuka, Bernadett, et al.
Publicado: (2023)

The effect of orofacial complete Freund’s adjuvant treatment on the expression of migraine-related molecules
por: Körtési, Tamás, et al.
Publicado: (2019)

Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC
por: Körtési, Tamás, et al.
Publicado: (2018)

Interictal brain activity differs in migraine with and without aura: resting state fMRI study
por: Faragó, Péter, et al.
Publicado: (2017)

Release of PACAP-38 in episodic cluster headache patients – an exploratory study
por: Tuka, Bernadett, et al.
Publicado: (2016)

From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment
por: Tanaka, Masaru, et al.
Publicado: (2023)

Are Migraine With and Without Aura Really Different Entities?
por: Kincses, Zsigmond Tamás, et al.
Publicado: (2019)

Therapeutic Approaches for Peripheral and Central Neuropathic Pain
por: Szok, Délia, et al.
Publicado: (2019)

Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis
por: Aczél, Timea, et al.
Publicado: (2021)

Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain
por: Cseh, Edina K., et al.
Publicado: (2020)

Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms
por: Körtési, Tamás, et al.
Publicado: (2022)

Evidence for Plastic Processes in Migraine with Aura: A Diffusion Weighted MRI Study
por: Szabó, Nikoletta, et al.
Publicado: (2018)

TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine
por: Spekker, Eleonóra, et al.
Publicado: (2022)

Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress
por: Aczél, Timea, et al.
Publicado: (2022)

EHMTI-0189. Tryptophan-kynurenine metabolism in migraine patients
por: Majláth, Z, et al.
Publicado: (2014)

Ictal and interictal brain activation in episodic migraine: Neural basis for extent of allodynia
por: Maleki, Nasim, et al.
Publicado: (2021)

Kynurenines, neurodegeneration and Alzheimer’s disease
por: Kincses, Zsigmond Tamas, et al.
Publicado: (2010)

Altered Resting State Functional Activity and Microstructure of the White Matter in Migraine With Aura
por: Faragó, Péter, et al.
Publicado: (2019)

Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems
por: Bartos, Csilla, et al.
Publicado: (2018)

Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach
por: Katona, Gábor, et al.
Publicado: (2020)

Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine
por: Nagy-Grócz, Gábor, et al.
Publicado: (2017)

Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity
por: Ambrus, Rita, et al.
Publicado: (2020)

Interictal plasma glutamate levels are elevated in individuals with episodic and chronic migraine
por: Park, Chae Gyu, et al.
Publicado: (2022)

Kynurenine Metabolites and Migraine: Experimental Studies and Therapeutic Perspectives
por: Fejes, Annamária, et al.
Publicado: (2011)

Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives
por: Biernacki, Tamás, et al.
Publicado: (2020)

The Tryptophan-Kynurenine Metabolic System Is Suppressed in Cuprizone-Induced Model of Demyelination Simulating Progressive Multiple Sclerosis
por: Polyák, Helga, et al.
Publicado: (2023)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
por: Szok, Délia, et al.
Publicado: (2015)

Indoleamine 2,3-Dioxygenase Cannot Inhibit Chlamydia trachomatis Growth in HL-60 Human Neutrophil Granulocytes
por: Virok, Dezső P., et al.
Publicado: (2021)

Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid
por: Tóth, Fanni, et al.
Publicado: (2021)

Citalopram Neuroendocrine Challenge Shows Altered Tryptophan and Kynurenine Metabolism in Migraine
por: Gecse, Kinga, et al.
Publicado: (2022)

Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review
por: Szok, Délia, et al.
Publicado: (2023)

Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions
por: Zádor, Ferenc, et al.
Publicado: (2019)

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain
por: Tajti, János, et al.
Publicado: (2023)

An Extensive Study of Phenol Red Thread as a Novel Non-Invasive Tear Sampling Technique for Proteomics Studies: Comparison with Two Commonly Used Methods
por: Kecskeméti, Gábor, et al.
Publicado: (2022)

Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations
por: Bohár, Zsuzsanna, et al.
Publicado: (2015)

Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists
por: Szűcs, Edina, et al.
Publicado: (2020)

Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
por: Bartos, Csaba, et al.
Publicado: (2019)

Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression
por: Zádor, Ferenc, et al.
Publicado: (2021)

Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis—Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines
por: Fakan, Bernadett, et al.
Publicado: (2019)

Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection
por: Sas, Katalin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rbd0rvk6rbuu3etcohdor8riup